Versartis, Inc.
4200 Bohannon Drive
Suite 250
Menlo Park
California
94025
United States
Tel: 650-963-8588
Website: http://www.versartis.com/
Email: info@versartis.com
94 articles about Versartis, Inc.
-
BioSpace Movers and Shakers Oct. 29
10/29/2018
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more. -
Versartis has retained Cowen to assist in evaluating its strategic options.
-
Bay Area Versartis's Stock Collapses as Growth Hormone Drug Flunks Phase III Test
9/25/2017
-
Versartis’ Twice-Monthly Somavaratan For Pediatric Growth Hormone Deficiency To Be Featured In Oral And Poster Presentations At IMPE 2017
9/8/2017
-
Versartis Announces Expansion Of Executive Leadership Team With Addition Of Dr. Robert Gut As The Head Of Global Clinical, Medical And Regulatory Affairs
9/6/2017
-
Versartis Reports Second Quarter 2017 Financial Results
7/28/2017
-
Versartis Presents 3-Year Somavaratan Safety And Efficacy Data And Pediatric Program Baseline Demographics At The 19th European Congress Of Endocrinology
5/22/2017
-
Versartis Reports First Quarter 2017 Financial Results
4/28/2017
-
Versartis Appoints Jay Stout, Ph.D., As Senior Vice President, Technical Operations
4/25/2017
-
Versartis Reports New Data On Long-Acting Somavaratan In Growth Hormone Deficiency At ENDO 2017
4/3/2017
-
Versartis Announces Three Year Somavaratan Data At ENDO 2017 Showing Safety And Efficacy In Line With Historical U.S. Daily rhGH Data In Pediatric GHD
4/3/2017
-
Versartis Presents Efficacy, Safety, Metabolic And Adherence Data For Somavaratan In Oral Session At The International Congress Of Endocrinology
9/6/2016
-
Bay Area's Versartis Strikes $165 Million Growth Hormone Deal With Teijin Limited
8/10/2016
-
Versartis, Inc. Presents Confirmatory 18-Month Adherence Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ENDO Annual Meeting
4/1/2016
-
Versartis, Inc. To Present At The Cowen and Company 36th Annual Health Care Conference
3/2/2016
-
Versartis, Inc. Reports Confirmatory Top-Line Two-Year Data From Ongoing Extension Study Of Somavaratan In GHD Children
2/2/2016
-
Versartis, Inc. To Present At The Credit Suisse 24th Annual Healthcare Conference
11/4/2015
-
Versartis, Inc. Reports Third Quarter 2015 Financial Results
10/30/2015
-
Versartis, Inc. Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ESPE Annual Meeting
10/1/2015
-
Versartis, Inc. Announces Confirmatory 18-Month Data From Ongoing Extension Study Of Somavaratan In GHD Children
9/18/2015